This landscape captures patent families whose claims or descriptions combine bio-based, biobased or biopolymer fiber materials with fiber testing, tensile testing or quality-inspection methods. That includes mechanical property testing such as tensile strength and modulus of elasticity, as well as biological and sterility testing where the fiber is intended for implant or medical use. It excludes filings on bio-based fibers generally that make no reference to a testing or inspection method, since the search string requires both elements to appear together.

The data shows 42 filings in 2021 against 6 at the 2022 midpoint, which is a sharp fall rather than a gradual decline. Some of that apparent drop is a publication-lag effect, since filings from the last one to two years are always undercounted at any given data cut-off. But the size of the gap between 2021 and 2022 is large enough that it likely also reflects a genuine slowdown in new filing activity after a concentrated push, possibly tied to a wave of implant or scaffold applications reaching the patent office around that time.

The recent-year momentum data shows every tracked assignee, including the most active named entities, at zero filings in the latest year, with several down 100% year on year from their prior activity. The strongest collaborative link in the dataset is between a German university and its affiliated university hospital, who co-file as a research pair. No single commercial assignee dominates the corpus of 102 families, which points to a fragmented field of academic, clinical and smaller company filers rather than one clear market leader.

Based on the IPC composition, claim density concentrates in sterilising and disinfecting (A61L), implants (A61F) and filament spinning (D01D), while detergent-compatibility testing, nonwoven-specific quality inspection, and automated inline defect detection for biopolymer fiber appear thinner in comparison. Filings outside the EPO, US and Australia are also comparatively rare, so jurisdictions like India and Canada may carry less prior art for an equivalent claim. Anyone evaluating a new filing should check these thinner branches against the fuller IPC table rather than assuming density is even across all classes.

Citation counts here should be read as a measure of influence within the searched corpus, not as a measure of current technical importance. The two most-cited records, both relating to composite mesh devices and biopolymer scaffold implants, date from earlier in the coverage window and have simply had more time to accumulate references from later filings. A recent filing with genuinely novel claims may show a low citation count for no reason other than its youth, so citation rank is best used alongside the filing-date and IPC data rather than on its own.